Skip to content 
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301; and collaboration and development agreement with Global Genes for treating rare ocular disorders. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California. more
| Time Frame | KPRX | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -2.34% | 0.72% | -1.31% |
| 1-Month Return | -5.43% | 1.27% | 0.78% |
| 3-Month Return | 0.97% | 3.13% | 3.46% |
| 6-Month Return | -27.43% | 15.81% | 6.19% |
| 1-Year Return | -43.82% | 8.89% | 11.68% |
| 3-Year Return | -96.22% | 20.79% | 71.21% |
| 5-Year Return | -99.92% | 35.89% | 74.81% |
| 10-Year Return | -99.99% | 138.44% | 256.59% |
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 12.06K | 12.06K | - | - | 16.00M | [{"date":"2020-12-31","value":0.08,"profit":true},{"date":"2021-12-31","value":0.08,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Cost of Revenue | 3.27M | 227.27K | 134.03K | 4.03M | 379.51K | [{"date":"2020-12-31","value":81.27,"profit":true},{"date":"2021-12-31","value":5.64,"profit":true},{"date":"2022-12-31","value":3.33,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":9.42,"profit":true}] |
| Gross Profit | (3.26M) | (227.27K) | (134.03K) | (4.03M) | 16.00M | [{"date":"2020-12-31","value":-20.38,"profit":false},{"date":"2021-12-31","value":-1.42,"profit":false},{"date":"2022-12-31","value":-0.84,"profit":false},{"date":"2023-12-31","value":-25.17,"profit":false},{"date":"2024-12-31","value":100,"profit":true}] |
| Gross Margin | (27038.66%) | (1884.68%) | - | - | 100.00% | [{"date":"2020-12-31","value":-27038.66,"profit":false},{"date":"2021-12-31","value":-1884.68,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Operating Expenses | 3.61M | 14.24M | 12.31M | 12.59M | 11.49M | [{"date":"2020-12-31","value":25.35,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":86.47,"profit":true},{"date":"2023-12-31","value":88.42,"profit":true},{"date":"2024-12-31","value":80.71,"profit":true}] |
| Operating Income | (6.87M) | (14.24M) | (12.31M) | (12.59M) | 4.51M | [{"date":"2020-12-31","value":-152.29,"profit":false},{"date":"2021-12-31","value":-315.63,"profit":false},{"date":"2022-12-31","value":-272.92,"profit":false},{"date":"2023-12-31","value":-279.07,"profit":false},{"date":"2024-12-31","value":100,"profit":true}] |
| Total Non-Operating Income/Expense | 38.31K | 266.77K | (1.34M) | 330.76K | 2.38M | [{"date":"2020-12-31","value":1.61,"profit":true},{"date":"2021-12-31","value":11.2,"profit":true},{"date":"2022-12-31","value":-56.23,"profit":false},{"date":"2023-12-31","value":13.89,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Pre-Tax Income | (6.85M) | (13.96M) | (13.70M) | (12.42M) | 5.66M | [{"date":"2020-12-31","value":-121.03,"profit":false},{"date":"2021-12-31","value":-246.71,"profit":false},{"date":"2022-12-31","value":-242,"profit":false},{"date":"2023-12-31","value":-219.51,"profit":false},{"date":"2024-12-31","value":100,"profit":true}] |
| Income Taxes | 12.05K | (192.60K) | (113.01K) | 90.32K | 2.07M | [{"date":"2020-12-31","value":0.58,"profit":true},{"date":"2021-12-31","value":-9.33,"profit":false},{"date":"2022-12-31","value":-5.47,"profit":false},{"date":"2023-12-31","value":4.37,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Income After Taxes | (6.86M) | (13.77M) | (13.58M) | (12.51M) | 3.59M | [{"date":"2020-12-31","value":-190.88,"profit":false},{"date":"2021-12-31","value":-383.08,"profit":false},{"date":"2022-12-31","value":-377.88,"profit":false},{"date":"2023-12-31","value":-348.12,"profit":false},{"date":"2024-12-31","value":100,"profit":true}] |
| Income From Continuous Operations | (8.09M) | (16.39M) | (13.58M) | (12.74M) | 3.59M | [{"date":"2020-12-31","value":-225.11,"profit":false},{"date":"2021-12-31","value":-456.08,"profit":false},{"date":"2022-12-31","value":-377.88,"profit":false},{"date":"2023-12-31","value":-354.51,"profit":false},{"date":"2024-12-31","value":100,"profit":true}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Net Income | (6.86M) | (13.77M) | (13.58M) | (12.51M) | 3.59M | [{"date":"2020-12-31","value":-190.88,"profit":false},{"date":"2021-12-31","value":-383.08,"profit":false},{"date":"2022-12-31","value":-377.88,"profit":false},{"date":"2023-12-31","value":-348.12,"profit":false},{"date":"2024-12-31","value":100,"profit":true}] |
| EPS (Diluted) | (54.03) | (41.06) | (41.46) | (3.15) | (2.17) | [{"date":"2020-12-31","value":-5403,"profit":false},{"date":"2021-12-31","value":-4106,"profit":false},{"date":"2022-12-31","value":-4146,"profit":false},{"date":"2023-12-31","value":-315,"profit":false},{"date":"2024-12-31","value":-216.76,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| KPRX | |
|---|---|
| Cash Ratio | 7.51 |
| Current Ratio | 8.79 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| KPRX | |
|---|---|
| ROA (LTM) | -17.07% |
| ROE (LTM) | -32.58% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| KPRX | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.25 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.75 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| KPRX | |
|---|---|
| Trailing PE | NM |
| Forward PE | 2.41 |
| P/S (TTM) | 363.74 |
| P/B | 0.34 |
| Price/FCF | NM |
| EV/R | 569.41 |
| EV/Ebitda | NM |
Kiora Pharmaceuticals Inc (KPRX) share price today is $2.09
Yes, Indians can buy shares of Kiora Pharmaceuticals Inc (KPRX) on Vested. To buy
Yes, you can purchase fractional shares of Kiora Pharmaceuticals Inc (KPRX) via the Vested app. You can start investing in Kiora Pharmaceuticals Inc (KPRX) with a minimum investment of $1.
You can invest in shares of Kiora Pharmaceuticals Inc (KPRX) via Vested in three simple steps:
The 52-week high price of Kiora Pharmaceuticals Inc (KPRX) is $4.18. The 52-week low price of Kiora Pharmaceuticals Inc (KPRX) is $1.76.
The price-to-earnings (P/E) ratio of Kiora Pharmaceuticals Inc (KPRX) is
The price-to-book (P/B) ratio of Kiora Pharmaceuticals Inc (KPRX) is 0.34
The dividend yield of Kiora Pharmaceuticals Inc (KPRX) is 0.00%
The market capitalization of Kiora Pharmaceuticals Inc (KPRX) is $7.43M
The stock symbol (or ticker) of Kiora Pharmaceuticals Inc is KPRX
Consider the share price of Kiora Pharmaceuticals Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Kiora Pharmaceuticals Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Kiora Pharmaceuticals Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Kiora Pharmaceuticals Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Kiora Pharmaceuticals Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Kiora Pharmaceuticals Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
